tiprankstipranks
Trending News
More News >
Xoma Corp. (XOMA)
:XOMA

Xoma (XOMA) AI Stock Analysis

Compare
373 Followers

Top Page

XO

Xoma

(NASDAQ:XOMA)

Rating:56Neutral
Price Target:
$28.00
▲( 12.68% Upside)
Xoma scores a 56 overall, driven primarily by mixed financial performance and strong technical indicators. Despite solid revenue growth, profitability and cash flow challenges weigh heavily. The technical analysis suggests bullish momentum, but valuation concerns with a negative P/E ratio highlight ongoing financial struggles.
Positive Factors
Earnings
XOMA reported 1Q25 revenue of $15.9M, 90% above the estimate of $8.2M.
Pipeline Milestones
XOMA anticipates four major pipeline milestones in 2025, including potential EMA approval of Ojemda and topline results from seralutinib.
Portfolio Expansion
XOMA has expanded its commercial asset portfolio to six products recently, through acquisitions and internal growth, which is expected to boost revenues by over 20% annually.
Negative Factors
Competitive Lag
While XOMA has bounced back from post-COVID-19 lows, the shares have risen 50% from lows in 2023, but XOMA’s valuation still lags that of comparables.
Financial Management
XOMA allocated $65 million for strategic transactions for long-term growth potential.
Valuation
Despite a strong recovery from post-COVID-19 lows, XOMA's valuation still lags behind comparable companies, offering potential for rerating higher based on strong fundamentals and expanding visibility.

Xoma (XOMA) vs. SPDR S&P 500 ETF (SPY)

Xoma Business Overview & Revenue Model

Company DescriptionXOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
How the Company Makes MoneyXOMA Corporation generates revenue through a combination of licensing agreements, milestone payments, and royalties. The company licenses its proprietary antibody technologies to other pharmaceutical and biotechnology companies, which then use these technologies to develop and commercialize new drugs. As these partner companies advance through clinical trials and achieve regulatory approvals, XOMA receives milestone payments. Additionally, the company earns royalties on the sales of any successfully marketed products developed using its technologies. XOMA also strategically invests in early-stage biotech companies, potentially benefiting from equity appreciation and future revenue-sharing agreements.

Xoma Financial Statement Overview

Summary
Xoma faces considerable financial challenges, particularly in terms of profitability and cash flow management. Despite strong revenue growth in 2024, the company continues to report net losses and negative free cash flows, which could hinder long-term sustainability. The balance sheet remains relatively stable, but the increasing leverage and persistent operational losses pose significant risks.
Income Statement
40
Negative
Xoma shows significant volatility in its income statement. While the revenue in 2024 significantly increased compared to 2023, the net income continues to remain negative, indicating ongoing profitability challenges. The gross profit margin remains high, but the company struggles with negative EBIT and EBITDA margins, suggesting operational inefficiencies or high costs relative to revenue.
Balance Sheet
55
Neutral
The balance sheet presents a mixed picture. The debt-to-equity ratio is relatively moderate, but the equity ratio has decreased over recent years, indicating increased financial leverage. The return on equity is negative due to net losses, posing a risk to shareholder value. However, the company maintains a stable cash position, which supports its operations.
Cash Flow
35
Negative
Cash flow analysis reveals significant challenges, with negative operating and free cash flows indicating that the company is not generating enough cash from its operations to sustain itself. The free cash flow has shown fluctuations with no consistent growth trajectory, and the operating cash flow to net income ratio is unfavorable due to persistent losses.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
28.49M4.76M6.03M38.16M29.39M
Gross Profit
28.28M3.86M5.93M37.99M29.21M
EBIT
-39.98M-41.85M-17.41M17.53M12.42M
EBITDA
-5.42M-39.36M-16.84M16.52M13.81M
Net Income Common Stockholders
-13.82M-40.83M-17.10M15.80M13.30M
Balance SheetCash, Cash Equivalents and Short-Term Investments
105.18M153.45M58.16M94.10M84.22M
Total Assets
221.28M234.30M140.38M166.56M125.28M
Total Debt
119.20M124.45M34.00K229.00K21.26M
Net Debt
17.54M-28.84M-57.79M-93.10M-62.96M
Total Liabilities
139.36M145.58M16.37M24.69M38.86M
Stockholders Equity
81.92M88.72M124.01M141.88M86.42M
Cash FlowFree Cash Flow
-13.77M-18.18M-36.13M-3.82M8.88M
Operating Cash Flow
-13.75M-18.16M-12.88M22.68M10.09M
Investing Cash Flow
-28.26M-711.00K-20.22M-26.50M-209.00K
Financing Cash Flow
-11.13M120.59M-4.45M12.84M19.79M

Xoma Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price24.85
Price Trends
50DMA
22.56
Positive
100DMA
23.76
Positive
200DMA
26.19
Negative
Market Momentum
MACD
0.90
Positive
RSI
51.79
Neutral
STOCH
22.23
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XOMA, the sentiment is Neutral. The current price of 24.85 is below the 20-day moving average (MA) of 25.15, above the 50-day MA of 22.56, and below the 200-day MA of 26.19, indicating a neutral trend. The MACD of 0.90 indicates Positive momentum. The RSI at 51.79 is Neutral, neither overbought nor oversold. The STOCH value of 22.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for XOMA.

Xoma Risk Analysis

Xoma disclosed 1 risk factors in its most recent earnings report. Xoma reported the most risks in the “Legal & Regulatory” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
Q4, 2024

Xoma Peers Comparison

Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
56
Neutral
$297.38M-3.42%638.41%71.89%
53
Neutral
$5.14B3.03-43.89%2.83%16.75%-0.06%
52
Neutral
$262.24M-68.21%-97.15%54.85%
49
Neutral
$168.82M-21.32%27.07%6.74%
48
Neutral
$249.88M-8.38%3.18%-835.29%
44
Neutral
$456.63M-2159.50%14.39%
42
Neutral
$392.45M-257.38%-17.92%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
XOMA
Xoma
24.85
-0.06
-0.24%
VNDA
Vanda
4.33
-0.90
-17.21%
VSTM
Verastem
8.31
4.19
101.70%
PVLA
Palvella Therapeutics
23.72
13.24
126.34%
HUMA
Humacyte
2.53
-4.62
-64.62%
OABI
OmniAb
1.38
-3.01
-68.56%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.